RANTES/CCL5 Signaling from Jawbone Cavitations to Epistemology of Multiple Sclerosis – Research and Case Studies

References

• Rothwell NJ, Hopkins SJ. Inflammatory response: pathway across the blood–brain barrier: how cytokines can induce these effects has been a mystery as they are unlikely to cross the blood–brain barrier. Trends Neurosci. 1995;18:130–136. doi:10.1016/0166-2236(95)93890-A
   PubMed Web of Science ®Google Scholar
• Salgado A, Boveda JL, Monasierio J, et al. Inflammatory mediators and their influence on haemostasis. Haemostasis. 1994;24–132.
   Google Scholar
• Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson P, Ericsson-Dahlstrand A. Inflammatory response: pathway across the blood–brain barrier. Nature. 2001;410(6827):430–431. doi:10.1038/35068632
   PubMed Web of Science ®Google Scholar
• Ramesh G, MacLean A, Philipp M. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm. 2013;2013:1–20. doi:10.1155/2013/480739
   Web of Science ®Google Scholar
• Ransohoff RM. The chemokine system in neuroinflammation: an update. J Infect Dis. 2002;186(Suppl 2):S152–S156. doi:10.1086/344266
   Web of Science ®Google Scholar
• Adler MW, Rogers TJ. Are chemokines the third major system in the brain? J Leukoc Biol. 2005;78:1204–1209. doi:10.1189/jlb.0405222
   PubMed Web of Science ®Google Scholar
• van der Meer P, Ulrich AM, Gonzalez-Scarano F, Lavi E. Immunohistochemical analysis of CCR2, CCR3, CCR5 and CXCR4 in the human brain: potential mechanisms for HIV dementia. Exp Mol Pathol. 2000;69:192–201. doi:10.1006/exmp.2000.2336
   PubMed Web of Science ®Google Scholar
• Horuk R, Martin AW, Wang Z, et al. Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol. 1997;158:2882–2890.
   PubMed Web of Science ®Google Scholar
• Ubogu E, Callahan M, Tucky B, Ransohoff R. Determinants of CCL5-driven mononuclear cell migration across the blood–brain barrier. Implications for therapeutically modulating neuroinflammation. J Neuroimmunol. 2006;179(1–2):132–144. doi:10.1016/j.jneuroim.2006.06.004
   Web of Science ®Google Scholar
• Lechner J, von Baehr V. RANTES and fibroblast growth factor 2 in jawbone cavitations: triggers for systemic disease? Int J Gen Med. 2013;6:277–290. doi:10.2147/IJGM.S43852
   PubMedGoogle Scholar
• Lechner J, Rudi T, von Baehr V. Osteoimmunology of tumor necrosis factor-alpha, IL-6 and RANTES/CCL5: a review of known and poorly understood inflammatory patterns in osteonecrosis. Clin Cosmet Investig Dent. 2018;10:251–262. doi:10.2147/CCIDE.S184498
   Web of Science ®Google Scholar
• Lechner J, Schuett S, von Baehr V. Aseptic-avascular osteonecrosis: local “silent inflammation” in the jawbone and RANTES/CCL5 overexpression. Clin Cosmet Investig Dent. 2017;9:99–109. doi:10.2147/CCIDE.S149545
   PubMed Web of Science ®Google Scholar
• Lechner J. Validation of dental X-ray by cytokine RANTES – comparison of X-ray findings with cytokine overexpression in jawbone. Clin Cosmet Investig Dent. 2014;6:71–79. doi:10.2147/CCIDE.S69807
   Google Scholar
• Store G, Boysen M. Mandibular osteoradionecrosis: clinical behaviours and diagnostic aspects. Clin Otolaryngol. 2000;25:378–384. doi:10.1046/j.1365-2273.2000.00367.x
   PubMed Web of Science ®Google Scholar
• Lechner J, Zimmermann B, Schmidt M, von Baehr V. Ultrasound sonography to detect focal osteoporotic jawbone marrow defects: clinical comparative study with corresponding hounsfield units and RANTES/CCL5 expression. Clin Cosmet Investig Dent. 2020;12:205–216. doi:10.2147/CCIDE.S247345
   PubMed Web of Science ®Google Scholar
• Happel C, Steele AD, Finley MJ, Kutzler MA, Rogers TJ. DAMGO-induced expression of chemokines and chemokine receptors: the role of TGF-β1. J Leukoc Biol. 2008;83(4):956–963. doi:10.1189/jlb.1007685
   Web of Science ®Google Scholar
• Skurk T, Mack I, Kempf K, Kolb H, Hauner H, Herder C. Expression and secretion of RANTES (CCL5) in human adipocytes in response to immunological stimuli and hypoxia. Horm Metab Res. 2009;41:183–189. doi:10.1055/s-0028-1093345
   Web of Science ®Google Scholar
• Tran PB, Miller RJ. Chemokine receptors in the brain: a developing story. J Comp Neurol. 2003;457:1–6. doi:10.1002/cne.10546
   Web of Science ®Google Scholar
• Szczuciński A, Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand. 2007;115:137–146. doi:10.1111/j.1600-0404.2006.00749.x
   PubMed Web of Science ®Google Scholar
• Musante V, Longordo F, Neri E, et al. RANTES modulates the release of glutamate in human neocortex. J Neurosci. 2008;28:12231–12240. doi:10.1523/JNEUROSCI.3212-08.2008
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Rudick RA. Heat-shock proteins and autoimmunity: implications for multiple sclerosis. Ann Neurol. 1993;34:5–7. doi:10.1002/ana.410340104
   Web of Science ®Google Scholar
• Karpus WJ, Ransohoff RM. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J Immunol. 1998;161:2667–2671.
   PubMed Web of Science ®Google Scholar
• Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103:807–815. doi:10.1172/JCI5150
   PubMed Web of Science ®Google Scholar
• Valerio A, Ferrario M, Martinez FO, et al. Gene expression profile activated by the chemokine CCL5/ RANTES in human neuronal cells. J Neurosci Res. 2004;78:371–382. doi:10.1002/jnr.20250
   Web of Science ®Google Scholar
• Mori F, Nisticò R, Nicoletti CG, et al. RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis. Mult Scleros J. 2016;22(11):1–8. doi:10.1177/1352458515621796
   Web of Science ®Google Scholar
• Iarlori C, Reale M, Lugaresi A, et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J Neuroimmunol. 2000;107:100–107. doi:10.1016/S0165-5728(00)00261-7
   PubMed Web of Science ®Google Scholar
• Van Veen T, Nielsen J, Berkhof J, et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol. 2007;190:157–164. doi:10.1016/j.jneuroim.2007.08.005
   PubMed Web of Science ®Google Scholar
• Bolin LM, Murray R, Lukacs NW, et al. Primary sensory neurons migrate in response to the chemokine RANTES. J Neuroimmunol. 1998;81(1–2):49–57. doi:10.1016/S0165-5728(97)00158-6
   Web of Science ®Google Scholar
• Simpson JJ, Newcombe M, Cuzner M, et al. Expression of monocyte chemoattractant protein-1 and other β chemokines by resident and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol. 1998;84:238. doi:10.1016/S0165-5728(97)00208-7
   PubMed Web of Science ®Google Scholar
• Hvas J, McLean C, Justesen J, et al. Perivascular T cells express the proinflammatory chemokine RANTES mRNA in multiple sclerosis lesions. Scand J Immunol. 1997;46:195–203. doi:10.1046/j.1365-3083.1997.d01-100.x
   PubMed Web of Science ®Google Scholar
• Bulanova E, Bulfone-Paus S. P2 receptor-mediated signaling in mast cell biology. Purinergic Signal. 2010;6:3–17. doi:10.1007/s11302-009-9173-z
   PubMed Web of Science ®Google Scholar
• Feuser K, Thon KP, Bischoff SC, Lorentz A. Human intestinal mast cells are a potent source of multiple chemokines. Cytokine. 2012;58:178–185. doi:10.1016/j.cyto.2012.01.001
   PubMed Web of Science ®Google Scholar
• Skuljec J, Sun H, Pul R, et al. CCL5 induces a pro-inflammatory profile in microglia in vitro. Cell Immunol. 2011;270:164–171. doi:10.1016/j.cellimm.2011.05.001
   Web of Science ®Google Scholar
• Gade-Andavolu R, Comings DE, MacMurray J, et al. RANTES: a genetic risk marker for multiple sclerosis. Mult Scleros J. 2004;10(5):536–539. doi:10.1191/1352458504ms1080oa
   Web of Science ®Google Scholar
• Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physio-pathological implications. J Neurochem. 2002;82:1311–1329. doi:10.1046/j.1471-4159.2002.01091.x
   PubMed Web of Science ®Google Scholar
• Nomura S, Uehata S, Saito S, Osumi K, Ozeki Y, Kimura Y. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost. 2002;89(3):506–512.
   Web of Science ®Google Scholar
• Herder C, Illig T, Baumert J, et al. RANTES/CCL5 gene polymorphisms, serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA Augsburg case–cohort study, 1984–2002. Eur J Endocrinol. 2008;158:R1–R5. doi:10.1530/EJE-07-0686
   Web of Science ®Google Scholar
• Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis- a guide for therapeutic decisions? Circulation. 1999;100:55–60. doi:10.1161/01.CIR.100.1.55
   PubMed Web of Science ®Google Scholar
• Jedynak M. Serum concentrations of MCP-1and RANTES in patients during aortic surgery: the relationship with ischemia-reperfusion. Arch Immunol Ther Exp. 2004;52:201–207.
   Web of Science ®Google Scholar
• Rentzos M, Nikolaou C, Rombos A, et al. Circulating interleukin-15 and RANTES chemokine in MS patients: effect of treatment with methylprednisolone in patients with relapse. Neurol Res. 2010;32(7):684–689. doi:10.1179/016164109X12445616596247
   PubMed Web of Science ®Google Scholar
• Sindern E, Niederkinkhaus Y, Henschel M, Ossege LM, Patzold T, Malin JP. Differential release of beta-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2001;104(2):88–91. doi:10.1034/j.1600-0404.2001.104002088.x
   PubMed Web of Science ®Google Scholar
• Lechner J, Huesker K, von Baehr V. Impact of RANTES from jawbone on chronic fatigue syndrome. J Biol Regul Homeost Agents. 2017;31(2):321–327.
   PubMed Web of Science ®Google Scholar